OctoPlus has entered into feasibility agreement with a biopharmaceutical company for the development of a controlled release formulation.
Subscribe to our email newsletter
OctoPlus is a European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries.
As per the agreement OctoPlus is expected to deveop a controlled release formulation of an undisclosed peptide compound.
If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Financial terms of the agreement are not disclosed.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.